Upadacitinib + Topical Corticosteroids for Eczema (AD Up Trial)

"This study is no longer admitting participants. It was originally posted on 8/9/2018 and last updated on 3/8/2022. However, there are presently 257 studies actively admitting participants with eczema and 21 studies for Topical corticosteroids (TCS) looking for patients."

"Currently, this study is being conducted out of the Centre de recheche dermatologique du Quebec Metropolitain /ID# 205403 in Québec, Quebec, Tory P Sullivan, MD PA /ID# 201174 in North Miami Beach, Florida, and Clinical Research of West Florida, Inc /ID# 203643 in Clearwater. An additional 75 research sites are located throughout the country."

"The age range for this clinical trial is 12 to 75. There are 118 studies specifically designed for children and 200 trials available for seniors."

"Since 2015, medical researchers have been studying the efficacy of Topical corticosteroids (TCS). In 2015, 1629 patients were involved in a study sponsored by AbbVie. After this initial research was conducted, Topical corticosteroids (TCS) received Phase 3 drug approval. As of now, 21 live studies are being conducted for Topical corticosteroids (TCS), spanning 953 cities and 54 countries."

"The primary outcome of this trial is the percentage of participants achieving a validated investigator global assessment for atopic dermatitis (vIGA-AD) of 0 or 1 with a reduction from baseline of ≥ 2 points at week 16. Secondary outcomes include adolescents: percentage of participants achieving an EASI 75 response at week 2, which is defined as EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema"

"This medical trial is looking for 968 participants between the ages of 12 and 75 who have eczema. In order to be eligible, participants must also meet the following criteria: They must have a documented history of inadequate response to topical corticosteroids or topical calcineurin inhibitor OR systemic treatment for AD within 6 months prior to Baseline Visit, Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age, Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline Visit and subject meets Hanifin and Rajka criteria., Active"

"Corticosteroids that are applied topically have shown efficacy in Phase 3 trials and multiple rounds of data support its safety, so it received a score of 3."

"Topical corticosteroids (TCS) are most often used on patients that may require systemic therapy. Additionally, this medication can help those suffering from rheumatoid arthritis, methotrexate, and other issues not responding well to conventional treatment plans."

"Currently, this trial is not looking for new patients. However, there are 257 other clinical trials involving eczema and 21 studies concerning Topical corticosteroids (TCS) that are still recruiting participants."

"At the moment, there are 21 different clinical trials underway that focus on Topical corticosteroids (TCS). Of those, 14 have progressed to Phase 3. Although a majority of these studies originate in Belgrade, Beograd, one can find 3924 locations running similar research worldwide."